# A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer

> **NCT00732056** · PHASE1 · COMPLETED · sponsor: **Geron Corporation** · enrollment: 24 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** GRN163L

## Key facts

- **NCT ID:** NCT00732056
- **Lead sponsor:** Geron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-09
- **Final completion:** 2012-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00732056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00732056, "A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00732056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*